Observations placeholder
Rozerem
Identifier
015705
Type of Spiritual Experience
Number of hallucinations: 73
Background
A description of the experience
Ramelteon, marketed as Rozerem is “the first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABAA receptors. Ramelteon is approved by the U.S. Food and Drug Administration (FDA) for long-term use”.
Ramelteon does not show any appreciable binding to GABAA receptors, which are associated with anxiolytic, myorelaxant, and amnesic effects.
Rozerem is used for insomnia, particularly ‘delayed sleep onset’.
On Dec, 30, 2016 4,504 people reported to have side effects when taking Rozerem.
Among them, 73 people (1.62%) have Hallucination
Time on Rozerem when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 84.62% | 3.85% | 3.85% | 7.69% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Rozerem :
| Female | Male | |
| Hallucination | 59.32% | 40.68% |
Age of people who have Hallucination when taking Rozerem :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 5.26% | 0.00% | 5.26% | 21.05% | 13.16% | 55.26% |